The Immunology and Safety of Maternal RSV Vaccination (ABRYSVO), Infant Nirsevimab (BEYFORTUS) Immunization, or Both Products

NCT06551506 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

181

Enrollment

NIH

Sponsor class

Conditions

Respiratory Syncytial Virus Infection

Interventions

BIOLOGICAL: Abrysvo
BIOLOGICAL: Beyfortus

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)